Cynosure Group
UTHR icon

Cynosure Group’s United Therapeutics UTHR Stock Holding History

Cynosure Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,114
Closed -$604K – 202
2026
Q2 		$604K Buy
+1,114
New +$627K 0.09% 132
2026
Q1 		– Sell
-1,050
Closed -$512K – 460
2025
Q4 		$512K Buy
+1,050
New +$489K 0.05% 155

Other funds holding UTHR

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Cynosure Group's UTHR Position: Q3 2026 in Review

Cynosure Group sold out of United Therapeutics (UTHR) in Q3 2026, closing a stake of 1,114 shares — an estimated $604K sold.

Cynosure Group first reported a position in UTHR in Q4 2025 and held it in 2 quarters. The position peaked at $604K in Q2 2026. 617 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Cynosure Group reported no remaining United Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Cynosure Group sold 1,114 United Therapeutics shares in Q3 2026, an estimated $604K.
  • Cynosure Group first reported a position in United Therapeutics in Q4 2025 and held it in 2 quarters.
  • Cynosure Group's United Therapeutics position peaked at $604K in Q2 2026.
  • 617 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Cynosure Group's 13F filing for Q3 2026, filed 3 Nov 2026.